C-TIL051 / AbelZeta Pharma - LARVOL DELTA

C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: AbelZeta Inc. | N=20 ➔ 1 | Trial completion date: Aug 2027 ➔ Dec 2025 | Recruiting ➔ Terminated; Sponsor decision

Enrollment change • Trial completion date • Trial termination • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: AbelZeta, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: AbelZeta, Inc.

Metastases • Trial completion date • Trial primary completion date • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer (PRNewswire) - "Nektar Therapeutics...announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ('CBMG'). The study will evaluate Nektar's NKTR-255, a novel interleukin-15 (IL-15) receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy....Under the new collaboration, CBMG will add NKTR-255 to its ongoing CBMG-sponsored Phase 1 clinical trial evaluating C-TIL051 in NSCLC patients who have relapsed on or were refractory to anti-PD-1 therapy, which is being conducted at Duke Cancer Institute (NCT05676749). The study is expected to enroll a total of 20 patients."

Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Cellular Biomedicine Group, Inc. | Initiation date: Mar 2023 ➔ Dec 2023

Metastases • Trial initiation date • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Cellular Biomedicine Group, Inc.

Metastases • New P1 trial • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Cellular Biomedicine Group Announces FDA Clearance of IND Application for Novel TIL Therapy C-TIL051 (PRNewswire) - "Cellular Biomedicine Group Inc...announced that the Food and Drug Administration (FDA) granted clearance of the Investigational New Drug (IND) application to proceed with Phase 1 clinical development of its novel Tumor Infiltrating Lymphocyte (TIL) product C-TIL051 for late-stage Non-Small Cell Lung Cancer (NSCLC) patients that are relapsed or refractory to anti-PD1 therapy...'We are working closely with clinical sites and plan to initiate the C-TIL051 Phase 1 trial soon,' said Tony (Bizuo) Liu, Chairman and CEO of CBMG. 'FDA clearance of the C-TIL051 IND is a significant milestone for CBMG. We plan to start manufacture of clinical batches of C-TIL051 in our GMP facility at Rockville Maryland in the near future'."

IND • Lung Cancer • Non Small Cell Lung Cancer • Oncology